0001209191-23-019743.txt : 20230317
0001209191-23-019743.hdr.sgml : 20230317
20230317170345
ACCESSION NUMBER: 0001209191-23-019743
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230317
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Manion Douglas J.
CENTRAL INDEX KEY: 0001875875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 23743612
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 640 LEE ROAD, SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-17
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001875875
Manion Douglas J.
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
1
0
0
Pres and CEO
Common Stock
2023-03-17
4
P
0
6300
7.8623
A
12800
D
The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-03-17